Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin therapeutic drug monitoring study in gram-negative bacterial infection
ChiCTR1900025622Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amikacin in Gram-negative bacterial infection, sponsored by Huashan Hospital. Primary endpoint: Efficacy and safety. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
amikacin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR1900025622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025622.